Posts by Vincent

2 weeks ago

Egle Therapeutics receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030

Egle Therapeutics receives significant non-dilutive funding to accelerate the clinical development of its lead immuno-oncology therapeutic candidate, EGL-001, as part of the “Innovations in Biotherapies and Bioproduction” call for projects…

2 months ago

IO360 Summit

Dates : March 24 – March 26 2025Location : Boston, MA Link : https://io360summit.com

3 months ago

EGLE Therapeutics Strengthens its Executive Leadership team with the Appointment of Christophe Quéva, Ph.D, as Chief Executive Officer

Paris, France, January 13th, 2025 – Egle Therapeutics, a clinical-stage biotechnology company advancing the next generation of regulatory T cell (Treg)-focused therapies for oncology and autoimmune diseases, today announced the…

5 months ago

Society for Immunotherapy of Cancer (SITC)

Location: Houston, USA Dates: November 6-10, 2024

5 months ago

Egle Therapeutics to share preclinical efficacy data for EGL-001, a CTLA-4/CD25 antagonist fusion protein at the Society for Immunotherapy of Cancer Meeting

Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, will present at the Society for Immunotherapy of Cancer Meeting…

7 months ago

ESMO

Location: Barcelona, Spain Dates: September 13-17, 2024

7 months ago

EGLE Therapeutics Strengthens its Board of Directors with the Appointment of Michel Detheux, Ph.D, as Independent Chairman Board Member, and with the Appointment of Mojgan Hossein-Nia, Ph.D. as Board member representative of Takeda Ventures

EGLE Therapeutics Strengthens its Board of Directors with the Appointment of Michel Detheux, Ph.D, as Independent Chairman Board Member, and with the Appointment of Mojgan Hossein-Nia, Ph.D. as Board member…

7 months ago

Interleukin-2 | The Promise of IL-2 Therapy

Location: Paris France Dates: September 4-7, 2024

9 months ago

Egle Therapeutics to share preclinical data for its first autoimmune disease program, EGL-003, with an oral presentation at the 2024 Promise of Interleukin-2 Therapy Meeting

Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, will deliver an oral presentation at The Promise of Interleukin-2…